SubHero Banner

Kalydeco® (ivacaftor) – Expanded indication

August 1, 2017 – Vertex announced the FDA approval of Kalydeco (ivacaftor) for use in more than 600 patients ≥ 2 years of age with cystic fibrosis (CF) who have one of five residual function mutations that result in a splicing defect in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Download PDF